1191 ATG-021, a novel 2+1 CD3-based T cell engager (TCE) targeting GPRC5D, demonstrates potent in vivo anti-tumor efficacy with low cytokine release

• Tengteng Li,
• Hui Yuwen,
• Bing Hou,
• Jay Mei,
• Bo Shan,
• Yijing Ren

Affiliations

Tengteng Li

Nursing Department of Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China

Hui Yuwen

2Antengene Corporation Co., Ltd, Shanghai, China

Bing Hou

2Antengene Corporation Co., Ltd, Shanghai, China

Jay Mei

3Antengene Corporation Co., Ltd, Shaoxing, Zhejiang, China

Bo Shan

3Antengene Corporation Co., Ltd, Shaoxing, Zhejiang, China

Yijing Ren

1Antengene Corporation Co., Ltd, Shanghai, China